Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naohiro Oda

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Journal of Cancer Research and Clinical Oncology|October 29, 2022
More than one-third of advanced non-small-cell lung cancer patients do not receive immunochemotherapy due to intoleranceChihiro Ando, Eiki Ichihara, Toshihide Yokoyama, et al.
Scientific Reports|April 4, 2023
Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosisKatsuyoshi Tomomatsu, Hirotaka Yasuba, Takashi Ishiguro, et al.
Cureus|June 27, 2025
Association Between Initial Symptoms and Clinical Outcomes in COVID-19Eiki Ichihara, Toshiharu Mitsuhashi, Mitsuru Tsuge, et al.
Cancers|December 17, 2024
Frequency and Significance of Body Weight Loss During Immunochemotherapy in Patients with Advanced Non-Small Cell Lung CancerMasataka Taoka, Eiki Ichihara, Toshihide Yokoyama, et al.
International Journal of Molecular Sciences|August 10, 2024
Increased Oxidative Stress and Decreased Citrulline in Blood Associated with Severe Novel Coronavirus Pneumonia in Adult PatientsMitsuru Tsuge, Eiki Ichihara, Kou Hasegawa, et al.
Clinical Lung Cancer|August 11, 2016
Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403Naohiro Oda, Eiki Ichihara, Katsuyuki Hotta, et al.
Plos One|August 28, 2020
Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤ 50%: A multi-center retrospective analysisSatoru Senoo, Nobuaki Miyahara, Akihiko Taniguchi, et al.
International Journal of Cancer|January 10, 2024
Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancerAyako Morita, Eiki Ichihara, Koji Inoue, et al.
Oncology Letters|November 16, 2020
Detection of epidermal growth factor receptor mutations in exhaled breath condensate using droplet digital polymerase chain reactionKazuya Nishii, Kadoaki Ohashi, Tomoki Tamura, et al.
Clinical Lung Cancer|July 14, 2016
Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405)Hideko Isozaki, Katsuyuki Hotta, Eiki Ichihara, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Journal of Cancer Research and Clinical Oncology|October 29, 2022
More than one-third of advanced non-small-cell lung cancer patients do not receive immunochemotherapy due to intoleranceChihiro Ando, Eiki Ichihara, Toshihide Yokoyama, et al.
Scientific Reports|April 4, 2023
Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosisKatsuyoshi Tomomatsu, Hirotaka Yasuba, Takashi Ishiguro, et al.
Cureus|June 27, 2025
Association Between Initial Symptoms and Clinical Outcomes in COVID-19Eiki Ichihara, Toshiharu Mitsuhashi, Mitsuru Tsuge, et al.
Cancers|December 17, 2024
Frequency and Significance of Body Weight Loss During Immunochemotherapy in Patients with Advanced Non-Small Cell Lung CancerMasataka Taoka, Eiki Ichihara, Toshihide Yokoyama, et al.
International Journal of Molecular Sciences|August 10, 2024
Increased Oxidative Stress and Decreased Citrulline in Blood Associated with Severe Novel Coronavirus Pneumonia in Adult PatientsMitsuru Tsuge, Eiki Ichihara, Kou Hasegawa, et al.
Clinical Lung Cancer|August 11, 2016
Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403Naohiro Oda, Eiki Ichihara, Katsuyuki Hotta, et al.
Plos One|August 28, 2020
Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤ 50%: A multi-center retrospective analysisSatoru Senoo, Nobuaki Miyahara, Akihiko Taniguchi, et al.
International Journal of Cancer|January 10, 2024
Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancerAyako Morita, Eiki Ichihara, Koji Inoue, et al.
Oncology Letters|November 16, 2020
Detection of epidermal growth factor receptor mutations in exhaled breath condensate using droplet digital polymerase chain reactionKazuya Nishii, Kadoaki Ohashi, Tomoki Tamura, et al.
Clinical Lung Cancer|July 14, 2016
Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405)Hideko Isozaki, Katsuyuki Hotta, Eiki Ichihara, et al.
Pageof 7